title: MUC1 has prognostic significance in malignant peritoneal mesothelioma.
abstract: BACKGROUND
  Overexpression of MUC1 predicts poor survival in most cancers. Routine immunohistochemical detection of MUC1 is performed for differential diagnosis in malignant peritoneal mesothelioma (MPM). However, the prognostic significance of MUC1 in MPM has not been determined.
  
  
  METHODS
  We investigated MUC1 expression and other prognostic factors in relation to survival in 42 patients (20 males and 22 females) for whom archival samples were available, using immunohistochemistry. MUC1 was expressed in 38/42 (90%) patients. Its prognostic significance was statistically analyzed using the Kaplan-Meier method.
  
  
  RESULTS
  High expression of MUC1 (immunohistochemical score of 5-8), was correlated with poor survival in several categories: all subtypes of tumors (p=0.001), male gender (p=0.017), female gender (p=0.001), epitheloid tumors (p=0.001), epitheloid tumors in males (p=0.005), epitheloid tumors in females (p=0.003), and age at diagnosis (AAD) <60 years (p=0.001). Amongst the other clinicopathological variables, univariate analysis also showed that male gender (p=0.007), sarcomatoid histology (p=0.001), peritoneal cancer index (PCI) ≥20 (p=0.013) and AAD ≥60 (p=0.001), correlated with poor survival. Multivariate analysis showed that only AAD ≥60 (p=0.049) was an independent prognostic factor, and that high MUC1 expression significantly correlated with the following categories: all subtypes of tumors (p=0.001), male gender (p=0.002), female gender (p=0.031), epitheloid tumors (p=0.031), and AAD <60y (p=0.012).
  
  
  CONCLUSIONS
  AAD and high MUC1 expression in the tumor are indicators of poor prognosis. MUC1 evaluation by immunohistochemistry may serve as a useful prognostic tool in MPM, but may need further confirmation in a larger patients' cohort.
authors.affiliation: Department of Surgery, University of New South Wales, St. George Hospital, Kogarah, NSW - Australia.
authors.forename: Krishna
authors.initials: K
authors.lastname: Pillai
authors.forename: Mohammad H
authors.initials: MH
authors.lastname: Pourgholami
authors.forename: Terence C
authors.initials: TC
authors.lastname: Chua
authors.forename: David L
authors.initials: DL
authors.lastname: Morris
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008654:Mesothelioma / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D000086002:Mesothelioma, Malignant; D008875:Middle Aged; D018396:Mucin-1 / Q000378:metabolism*; D010997:Pleural Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D018396:Mucin-1